Adeno-associated virus for cancer gene therapy

Cancer Research

Volumn 61, Issue 17, 2001, Pages 6313-6321

  Ponnazhagan, S ^a   Curiel, D T ^a   Shaw, D R ^a   Alvarez, R D ^a   Siegal, G P ^a  

^a University of Alabama at Birmingham   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLASMID VECTOR;

ADENOVIRUS; ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; CANCER GENETICS; CANCER THERAPY; CYTOTOXICITY; GENETIC TRANSDUCTION; IMMUNOTHERAPY; PRIORITY JOURNAL; REVIEW; TRANSCRIPTION REGULATION; TRANSGENE; VIRUS CAPSID; VIRUS REPLICATION;

ADENOVIRIDAE; ANIMALS; GENE THERAPY; GENETIC VECTORS; HUMANS; NEOPLASMS;

EID: 0035418150     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (154)

1. Adenovirus-associated defecive virus particles
2. Studies of small DNA viruses found in various adenovirus preparations: Physical, biological and immunological characteristics
3. Herpes simplex virus types 1 and 2 completely help adenovirus-associated virus replication
4. Vaccinia virus, herpes simplex virus, and carcinogens induce DNA amplification in a human cell line and support replication of a helper virus dependent Parvovirus
5. Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells
6. A human Parvoviryus, adeno-associated virus, as a eukaryotic vector: Transient expression and encapsidation of the prokaryotic gene for chloramphenicol acetyltransferase
7. Adeno-associated virus 2-mediated transduction of murine repopulating hematopoietic stem cells and long-term expression of a human globin gene in vivo
8. Long-term genetic modification of rhesus monkey hematopoietic cells following transplantation of adenoassociated virus vector-transduced CD34+ cells
9. Adeno-associated virus as a vector for liver-directed gene therapy
10. In vivo expression of therapeutic human genes for dopamine production in the caudates of MPTP-treated monkeys using an AAV vector
11. Adeno-associated virus-mediated delivery of erythropoietin leads to sustained elevation of hematocrit in nonhuman primates
12. rAAV vector-mediated sarcoglycan gene transfer in a hamster rodent model for limb girdle muscular dystrophy
13. Sustained correction of bleeding disorder in hemophilia B mice by gene therapy
14. Adeno-associated viral vector-mediated vascular endothelial growth factor gene transfer induces neovascular formation in ischemic heart
15. A Phase I study of an adeno-associated virus-CFTR gene vector in adult CF patients with mild lung disease
16. A Phase I/II study of tgAAV-CF for the treatment of chronic sinusitis in patients with cystic fibrosis
17. Evidence for gene transfer and expression of factor IX in haemophilia B patients treated with an AAV vector
18. Helper-free stocks of recombinant adeno-associated viruses: Normal integration does not require viral gene expression
19. Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers
20. Inhibition of adenovirus oncogenicity in hamsters by adeno-associated virus DNA
21. Nucleotide sequence and organization of adeno-associated virus 2 genome
22. Genetics of adeno-associated virus: Isolation and preliminary characterization of adenoassociated virus type 2 mutants
23. Mapping of the 5′ termini of two adeno-associated virus 2 RNAs in the left half of the genome
24. Spliced adenovirus-associated virus R.N.A.
25. Transcripts of the adeno-associated virus genome: Mapping of the major RNAs
26. Definition of a novel promoter for the major adenovirus-associated virus mRNA
27. Identification of the trans-acting Rep proteins of adeno-associated virus by antibodies to a synthetic oligopeptide
28. Characterization of adeno-associated virus rep proteins in human cells by antibodies raised against rep expressed in Escherichia coli
29. The AAV origin binding protein Rep68 is an ATP-dependent site-specific endonuclease with DNA helicase activity
30. Identification of a DNA-binding domain in the amino terminus of adeno-associated virus Rep proteins
31. The Rep78 gene product of adenoassociated virus (AAV) self-associates to form a hexameric complex in the presence of AAV ori sequences
32. Positive and negative autoregulation of the adeno-associated virus type 2 genome
33. Sequences required for coordinate induction of adeno-associated virus p19 and p40 promoters by Rep protein
34. Mutational analysis of adeno-associated virus Rep protein-mediated inhibition of heterologous and homologous promoters
35. Adeno-associated virus (AAV) Rep proteins mediate complex formation between AAV DNA and its integration site in human DNA
36. Mutagenesis of an AUG codon in the adenoassociated virus rep gene: Effects on viral DNA replication
37. The Rep52 gene product of adeno-associated virus is a DNA helicase with 3-to-5 polarity
38. The adeno-associated virus (AAV) Rep protein acts as both a repressor and an activator to regulate AAV transcription during a productive infection
39. Lipofection of purified adeno-associated virus Rep68 protein: Toward a chromosome-targeting nonviral particle
40. Site-specific integration of an adeno-associated virus vector plasmid mediated by regulated expression of rep based on cre-loxp recombination
41. Genetic analysis of adeno-associated virus: Properties of deletion mutants constructed in vitro and evidence for an adeno-associated virus replication function
42. Infectious clones and vectors derived from adeno-associated virus (AAV) seroptypes other than AAV type 2
43. Cloning of adenoassociated virus type 4 (AAV4) and generation of recombinant AAV4 particles
44. Nucleotide sequence of the inverted terminal repetition in adeno-associated virus DNA
45. Expression of the cystic fibrosis transmembrane conductance regulator from a novel adeno-associated virus promoter
46. Cloning of adenoassociated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells
47. Cell lines for the production of recombinant adeno-associated virus
48. A new strategy for large-scale preparation of high-titer recombinant adeno-associated virus vectors by using packaging cell lines and sulfonated cellulose column chromatography
49. High-titer adeno-associated viral vectors from a Rep/Cap cell line and hybrid shuttle virus
50. Packaging cells based on inducible gene amplification for the production of adeno-associated virus vectors
51. Production of high-titer recombinant adenoassociated virus in the absence of helper adenovirus
52. Novel tools for the production and purification of recombinant adeno-associated virus vectors
53. Adeno-associated virus vectors can be efficiently produced without helper virus
54. A helper virus-free packaging system for recombinant adeno-associated virus vectors
55. Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield
56. Recombinant human Parvovirus B19 vectors: Erythroid cell-specific delivery and expression of transduced genes
57. Efficient transduction of human neurons with an adeno-associated virus vector
58. Adeno-associated virus-mediated gene delivery
59. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector
60. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions
61. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adenoassociated virus 2
62. αV,β5 Integrin: A co-receptor for adeno-associated virus 2 infection
63. Endocytosis, and nuclear trafficking of adeno-associated virus type 2 are controlled by racl and phosphatidylinositol-3 kinase activation
64. Infectious entry pathway of adenoassociated virus and adeno-associated virus vectors
65. Impaired intracellular trafficking of adeno-associated virus type 2 vectors limits efficient transduction of murine fibroblasts
66. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors
67. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis
68. Replication of adeno-associated virus in cells irradiated with UV light at 254 nm
69. DNA synthesis and topoisomerase inhibitors increase transduction by adeno-associated virus vectors
70. DNA-damaging agents greatly increase the transduction of nondividing cells by adeno-associated virus vectors
71. Recombinant adeno-assiciated virus for muscle directed gene therapy
72. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors
73. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus
74. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue
75. Sustained secretion of human α-1 antitrypsin from murine muscle transduced with adeno-associated virus vectors
76. Factors influencing adeno-associated virus-mediated gene transfer to human cystic fibrosis airway epithelial cells: Comparison with adenovirus vectors
77. Adeno-associated virus type 2-mediated gene transfer: Role of epidermal growth factor receptor protein tyrosine kinase in transgene expression
78. Role of tyrosine phosphorylation of a cellular protein in adeno-associated virus 2-mediated transgene expression
79. Adeno-associated virus 2-mediated transduction of primary human bone marrow derived CD34+ hematopoietic progenitor cells: Donor variation and correlation of expression with cellular differentiation
80. Long-term gene expression and phenotypic correction using adeno-associated virus vectors in the mammalian brain
81. Viral gene delivery selectively restores feeding and prevents lethality of dopamine-deficient mice
82. Adeno-associated virus (AAV) vector antisense gene transfer in vivo decreases GABA(A) α1 containing receptors and increases inferior collicular seizure sensitivity
83. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle
84. The kinetics of rAAV integration in the liver
85. Suppression of human α-globin gene expression mediated by the recombinant adeno-associated virus 2 based antisense vectors
86. Comparison of promoter strengths on gene delivery into mammalian brain cells using AAV vectors
87. Transfer of activation-dependent gene expression into T cell lines by recombinant adeno-associated virus
88. Kinetics of recombinant adeno-associated virus-mediated gene transfer
89. Improved muscle-derived expression of human coagulation factor IX from a skeletal actin/CMV hybrid enhancer/promoter
90. Regulation of gene expression in vivo following transduction by two separate rAAV vectors
91. Regulated delivery of therapeutic proteins after in vivo somatic cell gene transfer
92. Long-term regulated expression of growth hormone in mice after intramuscular gene transfer
93. Gene Therapy for cancer: What have we done and where are we going?
94. Tumor suppressor genes
95. Molecular themes in oncogenesis
96. Experimental and clinical studies of cytokine genemodified tumor cells
97. Paracrine cytokine adjuvants in cancer immunotherapy
98. Immunotherapy of cancer
99. Cytokine therapy for cancer
100. Gene-based strategies for the immunotherapy of cancer
101. Gilboa, Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo
102. Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA
103. Retrovirally transduced bone marrow-derived dendritic cells require CD4+ T cell help to elicit protective and therapeutic antitumor immunity
104. Bevan, Virus-mediated delivery of antigenic epitopes into dendritic cells as a means to induce CTL
105. Maturation of dendritic cells accompanies high-efficiency gene transfer by a CD40-targeted adenoviral vector
106. Adenoviral vectors targeted to CD40 enhance the efficacy of dendritic cell-based vaccination against human papillomavirus 16-induced tumor cells in a murine model
107. CD80 (B7-1) and CD86 (B7-2): Potential targets for immunotherapy?
108. Functional and molecular characterisation of tumor-infiltrating lymphocytes transduced with tumor necrosis factor-α cDNA for the gene therapy of cancers in humans
109. Effect of adeno-associated virus on cancer expression by herpesvirus-transformed hamster cells
110. Inhibition/stimulation of bovine papillomavirus by adeno-associated virus is time as well as multiplicity dependent
111. Adeno-associated virus inhibits human papillomavirus type 16: A viral interaction implicated in cervical cancer
112. Adeno-associated virus Rep78 inhibits oncogenic transformation of primary human keratinocytes by a human papillomavirus type 16-ras chimeric
113. Suppression of tumorigenicity in cervical carcinoma HeLa cells by an episomal form of adeno-associated virus
114. Binding of the human papillomavirus type 16 p97 promoter by the adenoassociated virus Rep78 major regulatory protein correlates with inhibition
115. Adeno-associated virus and development of cervical neoplasia
116. Down-regulation of the human c-fos and c-myc proto-oncogene promoters by adeno-associated virus Rep78
117. Inhibition of S-phase progression by adenoassociated virus Rep78 protein is mediated by hypophosphorylated pRb
118. Adeno-associated virus type 2 Rep78 induces apoptosis through caspase activation independently of p53
119. Inhibition by acyclovir of cell growth and DNA synthesis of cells biochemically transformed with herpes virus genetic information
120. Selective killing of AFP-positive hepatocellular carcinoma cells by adeno-assiciated virus transfer of the herpes simplex virus thymidine kinase gene
121. Tissue-specific expression of herpes simplex virus thymidine kinase gene delivered by adeno-associated virus inhibits the growth of human hepatocellular carcinoma in athymic mice
122. Adno-associated viral-mediated gene transfer to hepatoma: Thymidine kinase/interleukine 2 is more effective in tumor killing in a non-GCV (GCV)-treated than in GCV-treated animals
123. Adeno-associated virus vector containing thymidine kinase gene causes complete regression of intracerebrally implanted human gliomas in mice, in conjunction with ganciclovir administration
124. Recombinant adeno-associated virus for the generation of autologous, gene-modified tumor vaccines: Evidence for a high transduction efficiency into primary epithelial cancer cells
125. Cancer gene therapy using a novel adeno-associated virus vector expressing human wild-type p53
126. Tumor behavior in isolated perfused organs: in vitro growth and metastases of biopsy material in rabbit thyroid and canine intestinal segment
127. Tumor angiogenesis: Therapeutic implications
128. The rationale and future potential of angiogenesis inhibitors in neoplasia
129. Progress in antiangiogenic gene therapy of cancer
130. Mechanisms of tumor angiogenesis and therapeutic implications: Angiogenesis inhibitors
131. Adenovirusmediated gene transfer of endostatin in vivo results in high level of transgene expression and inhibition of tumor growth and metastases
132. Antiangiogenic gene therapy of cancer utilizing a recombinant adenovirus to elevate systemic endostatin levels in mice
133. Antiangiogenic gene therapy for cancer via systemic administration of adenoviral vectors expressing secretable endostatin
134. Paracfine expression of a native soluble vascular endothelial growth factor receptor inhibits tumor growth, metastasis, and mortality rate
135. Adenovirus-mediated delivery of antiangiogenic genes as an antitumor approach
136. Systemic inhibition of tumor growth and tumor metastases by intramuscular administration of the endostatin gene
137. Adenoassociated virus-mediated delivery of antiangiogenic factors as an antitumor strategy
138. Gene transfer of the costimulatory molecules B7-1 and B7-2 into human multiple myeloma cells by recombinant adeno-associated virus enhances the cytolytic T cell response
139. Construction and biological characterization of an interleukin-12 fusion protein (Flexi-12): Delivery to acute myeloid leukemic blasts using adenoassociated virus
140. Genetic immunization with adeno-associated virus vectors expressing herpes simplex virus type 2 glycoproteins B and D
141. Active immunization with tumor cells transduced by a novel AAV plasmid-based gene delivery system
142. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer
143. High-efficiency transfer of the T cell co-stimulatory molecule B7-2 to lymphoid cells using high-titer recombinant adeno-associated virus vectors
144. Recombinant adeno-associated virus expressing human papillomavirus type 16 E7 peptide DNA fused with heat shock protein DNA as a potential vaccine for cervical cancer
145. Induction of immunity to antigens expressed by recombinant adeno-associated virus depends on the route of administration
146. CD40 ligand-dependent activation of cytotoxic T lymphocytes by adeno-associated virus vectors in vivo: Role of immature dendritic cells
147. Transduction and utility of the granulocyte-macrophage colonystimulating factor gene into monocytes and dendritic cells by adeno-associated virus
148. Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: Implications for ex vivo immunotherapy
149. Development of novel cell surface CD34-targeted recombinant adeno-associated virus vectors for gene therapy
150. Genetic capsid modifications allow efficient re-targeting of adenoassociated virus type 2
151. Insertional mutagenesis of AAV2 capsid and the production of recombinant virus
152. Mutational analysis of the adeno-associated virus type 2 (AAV2) capsid gene and construction of AAV2 vectors with altered tropism
153. Targeted adeno-associated virus vector transduction of nonpermissive cells mediated by a bispecific F(ab′,γ)2 antibody